Neprilysin inhibitors
In one aspect, the invention relates to compounds having the formula: where X, R a , R b , R 2 , and R 7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
1. A compound having the structure:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 1 .
3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, a compound of claim 1 , and an AT 1 receptor antagonist.
4. The pharmaceutical composition comprising a pharmaceutically acceptable carrier, a compound of claim 1 , and a phosphodiesterase (PDE) inhibitor.
5. The pharmaceutical composition comprising a pharmaceutically acceptable carrier, a compound of claim 1 , and a renin inhibitor.
6. The pharmaceutical composition comprising a pharmaceutically acceptable carrier, a compound of claim 1 , and a diuretic.
7. A method for treating hypertension, heart failure, or renal disease, comprising administering to a patient a therapeutically effective amount of the compound of claim 1 .